Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.

Drake JA, Portnoy DC, Tauer K, Weksler B.

Ann Thorac Surg. 2018 Oct;106(4):959-965. doi: 10.1016/j.athoracsur.2018.04.074. Epub 2018 May 29.

PMID:
29856974
2.

Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).

Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14.

3.

Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.

Ecker BL, McMillan MT, Datta J, Lee MK, Karakousis GC, Vollmer CM Jr, Drebin JA, Fraker DL, Roses RE.

Cancer. 2017 May 15;123(6):967-976. doi: 10.1002/cncr.30439. Epub 2016 Nov 7.

4.

Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis.

Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR.

JAMA Oncol. 2018 Jan 1;4(1):31-38. doi: 10.1001/jamaoncol.2017.2805.

5.

Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.

Kim BH, Kim HJ, Wu HG, Kang CH, Kim YT, Lee SH, Kim DW.

Clin Lung Cancer. 2014 Sep;15(5):356-64. doi: 10.1016/j.cllc.2014.05.005. Epub 2014 Jun 6.

PMID:
24996882
6.

Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.

Chen Y, Peng X, Zhou Y, Xia K, Zhuang W.

World J Surg Oncol. 2018 Jan 16;16(1):8. doi: 10.1186/s12957-018-1313-x. Review.

7.

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.

Wakeam E, Acuna SA, Leighl NB, Giuliani ME, Finlayson SRG, Varghese TK, Darling GE.

Lung Cancer. 2017 Jul;109:78-88. doi: 10.1016/j.lungcan.2017.04.021. Epub 2017 May 1.

PMID:
28577955
8.

Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients.

Li J, Dai CH, Shi SB, Chen P, Yu LC, Wu JR.

Ann Thorac Med. 2009 Oct;4(4):201-7. doi: 10.4103/1817-1737.56010.

9.

Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

Bott MJ, Patel AP, Verma V, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V.

J Thorac Cardiovasc Surg. 2016 Jun;151(6):1549-1558.e2. doi: 10.1016/j.jtcvs.2016.01.058. Epub 2016 Mar 12.

10.

Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V.

J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.

11.

The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.

Sawabata N, Keller SM, Matsumura A, Kawashima O, Hirono T, Osaka Y, Maeda H, Fukai S, Kawahara M; Japan National Chest Hospital Study Group for Lung Cancer.

Lung Cancer. 2003 Oct;42(1):69-77.

PMID:
14512190
12.

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, De Ruysscher D, Belka C, Cordes S, Hepp R, Lütke-Brintrup D, Lehmann N, Schuler M, Jöckel KH, Stamatis G, Stuschke M.

J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.

PMID:
26527789
13.

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.

14.

Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.

Tanaka F, Yokomise H, Soejima T, Uramoto H, Yamanaka T, Nakagawa K, Yamamoto N, Nishimura Y, Niwa H, Okada M, Nakagawa T, Yamashita M.

Ann Thorac Surg. 2018 Oct;106(4):1018-1024. doi: 10.1016/j.athoracsur.2018.05.027. Epub 2018 Jun 8.

PMID:
29890150
15.

Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non-small cell lung cancer invading the chest wall.

Drake JA, Sullivan JL, Weksler B.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1794-1802. doi: 10.1016/j.jtcvs.2017.11.091. Epub 2017 Dec 19.

PMID:
29352585
16.

Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.

Yang CF, Adil SM, Anderson KL, Meyerhoff RR, Turley RS, Hartwig MG, Harpole DH Jr, Tong BC, Onaitis MW, D'Amico TA, Berry MF.

Eur J Cardiothorac Surg. 2016 Jun;49(6):1607-13. doi: 10.1093/ejcts/ezv431. Epub 2015 Dec 30.

17.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.

Herskovic A, Mauer E, Christos P, Nagar H.

J Thorac Oncol. 2017 Feb;12(2):302-313. doi: 10.1016/j.jtho.2016.09.135. Epub 2016 Oct 14.

18.

Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.

Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK.

Lung Cancer. 2011 Dec;74(3):446-50. doi: 10.1016/j.lungcan.2011.05.003. Epub 2011 Jun 14.

PMID:
21676484
19.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.

Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V.

J Thorac Oncol. 2016 Oct;11(10):1729-35. doi: 10.1016/j.jtho.2016.05.022. Epub 2016 Jun 8.

20.

Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.

Mahmoud O, Hathout L, Shaaban SG, Elshaikh MA, Beriwal S, Small W Jr.

Gynecol Oncol. 2016 Dec;143(3):539-544. doi: 10.1016/j.ygyno.2016.10.022. Epub 2016 Oct 18.

PMID:
27769525

Supplemental Content

Support Center